MO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Altria Group Inc (MO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has some positive catalysts, including bullish technical indicators and manageable risks highlighted by analysts, the company's recent financial performance shows significant declines in revenue, net income, and EPS. Additionally, there are no strong proprietary trading signals or significant recent trading trends to support an immediate buy decision. It is better to hold off for now and monitor the stock for improved financial performance or stronger market signals.
The technical indicators are bullish overall. The MACD histogram is positive and expanding, suggesting upward momentum. The RSI is in the neutral zone at 76.994, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 66.881), with the next resistance at R2: 68.689. However, the pre-market price is slightly down by -0.12%, indicating minor short-term weakness.
Analysts have raised price targets recently, with UBS and Citi highlighting manageable risks and potential for revenue growth in 2026-
The nicotine pouch market is projected to grow significantly, which could benefit Altria in the long term.
Bullish technical indicators suggest positive momentum in the stock price.
The company's Q4 2025 financials show a significant decline in revenue (-0.53% YoY), net income (-63.25% YoY), and EPS (-63.13% YoY), which raises concerns about its current operational efficiency.
Higher operating costs in key business segments (Smokable and Oral Products) have impacted performance.
No recent congress trading data or significant hedge fund/insider activity to indicate strong institutional confidence.
In Q4 2025, Altria's revenue dropped to $5.08 billion (-0.53% YoY), net income dropped to $1.11 billion (-63.25% YoY), and EPS dropped to $0.66 (-63.13% YoY). However, gross margin increased slightly to 70.66% (+0.11% YoY), indicating some operational efficiency improvement despite declining profitability.
Analysts have mixed views. UBS and Citi have raised price targets recently, citing manageable risks and potential for revenue growth in 2026-2027. However, Stifel lowered its price target, citing softer-than-expected operating performance and higher costs. The consensus rating appears to lean towards Neutral to Buy, but concerns about near-term fundamentals remain.
